Previous Article | Next Article ![]()
Journal of Virology, November 2007, p. 11992-12004, Vol. 81, No. 21
0022-538X/07/$08.00+0 doi:10.1128/JVI.01358-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Ben Buscher,1
Brian Geiss ,2,
Michael Engle,2
Robert M. Roth,1
Kyung Min Chung ,2,
Melanie Samuel,3 and
Michael S. Diamond2,3,4*
Apath, LLC, St. Louis, Missouri,1 Departments of Medicine,2 Molecular Microbiology,3 Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri4
Received 21 June 2007/ Accepted 31 July 2007
West Nile virus (WNV) has spread throughout the United States and Canada and now annually causes a clinical spectrum of human disease ranging from a self-limiting acute febrile illness to acute flaccid paralysis and lethal encephalitis. No therapy or vaccine is currently approved for use in humans. Using high-throughput screening assays that included a luciferase expressing WNV subgenomic replicon and an NS1 capture enzyme-linked immunosorbent assay, we evaluated a chemical library of over 80,000 compounds for their capacity to inhibit WNV replication. We identified 10 compounds with strong inhibitory activity against genetically diverse WNV and Kunjin virus isolates. Many of the inhibitory compounds belonged to a chemical family of secondary sulfonamides and have not been described previously to inhibit WNV or other related or unrelated viruses. Several of these compounds inhibited WNV infection in the submicromolar range, had selectivity indices of greater than 10, and inhibited replication of other flaviviruses, including dengue and yellow fever viruses. One of the most promising compounds, AP30451, specifically blocked translation of a yellow fever virus replicon but not a Sindbis virus replicon or an internal ribosome entry site containing mRNA. Overall, these compounds comprise a novel class of promising inhibitors for therapy against WNV and other flavivirus infections in humans.
Published ahead of print on 22 August 2007.
Present address: Vertex Pharmaceuticals, Inc., 130 Waverly St., Cambridge, MA 02139.
Present address: Department of Microbiology, Colorado State University, Fort Collins, CO 80523.
Present address: Department of Microbiology, Chonbuk National University Medical School, Chonju, Chonbuk 561-180, Republic of Korea.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»